Trial · NCT06323174
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06323174, Phase 3, Completed, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise. Trials, record NCT06323174. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06323174
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- NCT number
- NCT06323174
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 189 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- First posted
- 2024-03-21
- Last updated
- 2026-09-30
Source ClinicalTrials.gov
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to end of treatment (week 40) | Measured as percentage (%)-points. |
| Secondary | Relative change in body weight | From baseline (week 0) to end of treatment (week 40) | Measured in %. |
| Secondary | Number of participants who achieve greater than or equal to (>=) 10% body weight reduction | From baseline (week 0) to end of treatment (week 40) | Measured as count of participants. |
| Secondary | Number of participants who achieve >=15% body weight reduction | From baseline (week 0) to end of treatment (week 40) | Measured as count of participants. |
| Secondary | Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol]) | At end of treatment (week 40) | Measured as count of participants. |
| Secondary | Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol) | At end of treatment (week 40) | Measured as count of participants. |
| Secondary | Change in Fasting Plasma Glucose (FPG) | From baseline (week 0) to end of treatment (week 40) | Measured in millimoles per liter (mmol/L). |
| Secondary | Number of participants who achieve >=5% body weight reduction | From baseline (week 0) to end of treatment (week 40) | Measured as count of participants. |
| Secondary | Number of participants who achieve >=20% body weight reduction | From baseline (week 0) to end of treatment (week 40) | Measured as count of participants. |
| Secondary | Change in waist circumference | From baseline (week 0) to end of treatment (week 40) | Measured in centimeters (cm). |
1 to 10 of 31Source ClinicalTrials.gov
See all 31 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42251860 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06323174
GET https://conductscience.org/api/trials/v1/NCT06323174/registered?page=2